• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 18, 2019

View Archived Issues

Yale scientists restore function in pig brains post-mortem in NIH BRAIN-funded research

LONDON – Scientists have succeeded in restoring circulation and cellular functions in pig brains four hours post-mortem, providing the basis on which to develop powerful whole brain models for drug discovery and for studying the effects of ischemia and other injuries. Read More

Kiadis picks up NKC therapy firm Cytosen in potential $88M stock deal

DUBLIN – Kiadis Pharma NV is adding a natural killer cell (NKC) platform for improving the safety and efficacy of hematopoietic stem cell transplant (HSCT) to its existing T-cell therapy focused on the same goal by acquiring Cytosen Therapeutics Inc., in a stock-based transaction valued at just €19.4 million (US$21.9 million) initially, but which could be worth up to €77.5 million in total.  Read More

Go boldly? Or mind the unintended consequences?

As U.S. lawmakers ponder how to keep prescription drug prices from totally collapsing into a black hole from which there's no escape, they're fighting against counter gravitational pulls and trying to remove a lot of debris from the space. Read More

Thinking BIG: Puretech, BI unite to advance I-O candidates in $226M collaboration

Puretech Health plc entered a research collaboration with Boehringer Ingelheim GmbH to leverage Puretech's lymphatic targeting technology for immune modulation and develop product candidates for an undisclosed number of targets. Puretech receives up to $26 million in the deal and is eligible for more than $200 million in development and sales milestones, in addition to royalties on product sales. Read More

First-line gene therapy success reported for MB-107 in X-SCID

Several infants treated with autologous ex vivo gene therapy for newly diagnosed X-linked severe combined immunodeficiency (X-SCID) in a phase I/II trial have developed fully functioning immune systems, including T cells, B cells and natural killer cells. The results, which were published in the April 17, 2019, issue of The New England Journal of Medicine, mark the first time that first-line treatment with X-SCID gene therapy has resulted in an immune system that was able to generate not just T cells, but the major cell types of the innate and adaptive immune systems. Read More

Researchers unveil first anisotropic knee meniscus engineered from stem cells

A tissue-engineered knee meniscus, seeded with mesenchymal stem cells (MSCs) under biomechanical and biochemical stimuli in vitro, has been shown to promote anisotropy and have a functional chondroprotective effect on the knee, a Chinese study reported in the April 10, 2019, issue of Science Translational Medicine. Read More

Appointments and advancements

Amag Pharmaceuticals Inc., of Waltham, Mass., appointed Nancy Griffith vice president of scientific communications and medical operations and Anne Phillips and Kathrine O'Brien to its board. Read More

Financings

Phasebio Pharmaceuticals Inc., of Malvern, Pa., said it closed its underwritten public offering of 4.12 million shares that included 537,975 shares from the full exercise of the underwriters' option to purchase additional shares at $12 each. The gross proceeds from the offering were $49.5 million. Read More

Other news to note

Wuxi Biologics Inc., of Shanghai, said its drug substance and drug product manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo (ibalizumab), the first routine GMP inspection since the product's U.S. approval in March 2018.  Read More

Clinical data for April 17, 2019

Read More

Regulatory actions for April 17, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe